New drug cocktail aims to fight tough bile duct cancer
NCT ID NCT06548412
First seen Jun 24, 2026 · Last updated Jul 17, 2026 · Updated 3 times
Summary
This early-phase trial tests whether adding an experimental drug called CTX-009 to standard chemotherapy (gemcitabine and cisplatin) plus immunotherapy (durvalumab) can safely treat advanced biliary tract cancer that cannot be removed by surgery. About 50 adults will receive the combination intravenously. The main goal is to check for side effects, but researchers will also watch for signs that the tumors shrink or stop growing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CTX-009 (an experimental drug) combined with gemcitabine, cisplatin, and durvalumab
- What this could lead to
- If successful, this combination could improve tumor control and survival for people with advanced biliary tract cancer, a disease with limited treatment options.
- What could go wrong
- This is an early-phase trial with only 50 participants, so results may not apply broadly. Adding more drugs also raises the risk of side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.